AGENUS INC (AGEN:NASDAQ)
$4.15 0.19 (4.798%)
Analysed AGENUS INC (AGEN:NASDAQ) News Sources
Can Agenus (AGEN) Run Higher on Rising Earnings Estimates?
03-04-2026
yahoo.com
All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy
03-04-2026
yahoo.com
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?
03-04-2026
yahoo.com
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
03-04-2026
yahoo.com
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
01-04-2026
yahoo.com
Agenus AGM: Bot/Bal Combo Targets “Cold” MSS Colorectal Cancer as Phase III BATMAN Trial Launches
31-03-2026
marketbeat.com
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
26-03-2026
yahoo.com
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
17-03-2026
yahoo.com
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates
17-03-2026
yahoo.com
Agenus: Q4 Earnings Snapshot
16-03-2026
yahoo.com
What is the current price of AGENUS INC (AGEN:NASDAQ)?
The current price of AGENUS INC (AGEN:NASDAQ) is $4.15.
AGENUS INC (AGEN:NASDAQ) absolute price change since previous trading day?
The absolute price change of AGENUS INC (AGEN:NASDAQ) since the previous trading day is $0.19.
AGENUS INC (AGEN:NASDAQ) percentage price change since previous trading day?
The percentage price change of AGENUS INC (AGEN:NASDAQ) since the previous trading day is 4.798%.
What is the most recent average sentiment score for AGENUS INC (AGEN:NASDAQ)?
The most recent average sentiment score for AGENUS INC (AGEN:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for AGENUS INC (AGEN:NASDAQ)?
The most recent sentiment for AGENUS INC (AGEN:NASDAQ) is .
SEC-8K** Filing Available For AGENUS INC (AGEN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.